PURPOSE: Emerging clinical evidence suggests intravenous bisphosphonates may inhibit breast cancer while oral bisphosphonates have received limited evaluation regarding breast cancer influence. PATIENTS AND METHODS: The association between oral bisphosphonate use and invasive breast cancer was examined in postmenopausal women enrolled onto the Women's Health Initiative (WHI). We compared a published hip fracture prediction model, which did not incorporate bone mineral density (BMD), with total hip BMD in 10,418 WHI participants who had both determinations. To adjust for potential BMD difference based on bisphosphonate use, the hip fracture prediction score was included in multivariant analyses as a BMD surrogate. RESULTS: Of the 154,768 participants, 2,816 were oral bisphosphonate users at entry (90% alendronate, 10% etidronate). As calculated hip fracture risk score was significantly associated with both BMD (regression line = 0.79 to 0.0478 log predicted fracture; P < .001; r = 0.43) and breast cancer incidence (P = .03), this variable was incorporated into regression analyses to adjust for BMD difference between users and nonusers of bisphopshonate. After 7.8 mean years of follow-up (standard deviation, 1.7), invasive breast cancer incidence was lower in bisphosphonate users (hazard ratio [HR], 0.68; 95% CI, 0.52 to 0.88; P < .01) as was incidence of estrogen receptor (ER) -positive invasive cancers (HR, 0.70; 95% CI, 0.52 to 0.94, P = .02). A similar but not significant trend was seen for ER-negative invasive cancers. The incidence of ductal carcinoma in situ was higher in bisphosphonate users (HR, 1.58; 95% CI, 1.08 to 2.31; P = .02). CONCLUSION: Oral bisphosphonate use was associated with significantly lower invasive breast cancer incidence, suggesting bisphosphonates may have inhibiting effects on breast cancer.
PURPOSE: Emerging clinical evidence suggests intravenous bisphosphonates may inhibit breast cancer while oral bisphosphonates have received limited evaluation regarding breast cancer influence. PATIENTS AND METHODS: The association between oral bisphosphonate use and invasive breast cancer was examined in postmenopausal women enrolled onto the Women's Health Initiative (WHI). We compared a published hip fracture prediction model, which did not incorporate bone mineral density (BMD), with total hip BMD in 10,418 WHI participants who had both determinations. To adjust for potential BMD difference based on bisphosphonate use, the hip fracture prediction score was included in multivariant analyses as a BMD surrogate. RESULTS: Of the 154,768 participants, 2,816 were oral bisphosphonate users at entry (90% alendronate, 10% etidronate). As calculated hip fracture risk score was significantly associated with both BMD (regression line = 0.79 to 0.0478 log predicted fracture; P < .001; r = 0.43) and breast cancer incidence (P = .03), this variable was incorporated into regression analyses to adjust for BMD difference between users and nonusers of bisphopshonate. After 7.8 mean years of follow-up (standard deviation, 1.7), invasive breast cancer incidence was lower in bisphosphonate users (hazard ratio [HR], 0.68; 95% CI, 0.52 to 0.88; P < .01) as was incidence of estrogen receptor (ER) -positive invasive cancers (HR, 0.70; 95% CI, 0.52 to 0.94, P = .02). A similar but not significant trend was seen for ER-negative invasive cancers. The incidence of ductal carcinoma in situ was higher in bisphosphonate users (HR, 1.58; 95% CI, 1.08 to 2.31; P = .02). CONCLUSION: Oral bisphosphonate use was associated with significantly lower invasive breast cancer incidence, suggesting bisphosphonates may have inhibiting effects on breast cancer.
Authors: Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark Journal: JAMA Date: 2006-06-05 Impact factor: 56.272
Authors: Daniele Santini; Bruno Vincenzi; Sara Galluzzo; Fabrizio Battistoni; Laura Rocci; Olga Venditti; Gaia Schiavon; Silvia Angeletti; Federica Uzzalli; Michele Caraglia; Giordano Dicuonzo; Giuseppe Tonini Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: Christina A Clarke; Sally L Glaser; Connie S Uratsu; Joseph V Selby; Larry H Kushi; Lisa J Herrinton Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: Jacob A Udell; Michael A Fischer; M Alan Brookhart; Daniel H Solomon; Niteesh K Choudhry Journal: J Bone Miner Res Date: 2006-05 Impact factor: 6.741
Authors: B Fisher; J Dignam; N Wolmark; D L Wickerham; E R Fisher; E Mamounas; R Smith; M Begovic; N V Dimitrov; R G Margolese; C G Kardinal; M T Kavanah; L Fehrenbacher; R H Oishi Journal: Lancet Date: 1999-06-12 Impact factor: 79.321
Authors: G N Hortobagyi; R L Theriault; A Lipton; L Porter; D Blayney; C Sinoff; H Wheeler; J F Simeone; J J Seaman; R D Knight; M Heffernan; K Mellars; D J Reitsma Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry Journal: N Engl J Med Date: 2007-04-19 Impact factor: 91.245
Authors: Chris R Cardwell; Christian C Abnet; Philip Veal; Carmel M Hughes; Marie M Cantwell; Liam J Murray Journal: Int J Cancer Date: 2012-01-11 Impact factor: 7.396
Authors: Rebecca L Drieling; Andrea Z LaCroix; Shirley A A Beresford; Denise M Boudreau; Charles Kooperberg; Rowan T Chlebowski; Margery Gass; Carolyn J Crandall; Catherine R Womack; Susan R Heckbert Journal: Menopause Date: 2016-11 Impact factor: 2.953
Authors: Simon Junankar; Gemma Shay; Julie Jurczyluk; Naveid Ali; Jenny Down; Nicholas Pocock; Andrew Parker; Akira Nguyen; Shuting Sun; Boris Kashemirov; Charles E McKenna; Peter I Croucher; Alexander Swarbrick; Katherine Weilbaecher; Tri Giang Phan; Michael J Rogers Journal: Cancer Discov Date: 2014-10-13 Impact factor: 39.397